| __timestamp | BioCryst Pharmaceuticals, Inc. | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 20140000 |
| Thursday, January 1, 2015 | 13047000 | 37173000 |
| Friday, January 1, 2016 | 11253000 | 48616000 |
| Sunday, January 1, 2017 | 13933000 | 108488000 |
| Monday, January 1, 2018 | 29514000 | 244622000 |
| Tuesday, January 1, 2019 | 37121000 | 287000000 |
| Wednesday, January 1, 2020 | 67929000 | 354000000 |
| Friday, January 1, 2021 | 118818000 | 186000000 |
| Saturday, January 1, 2022 | 159371000 | 151000000 |
| Sunday, January 1, 2023 | 213894000 | 232600000 |
| Monday, January 1, 2024 | 267474000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, understanding financial health is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Ionis Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Ionis consistently outpaced BioCryst in SG&A spending, peaking in 2020 with expenses nearly 75% higher than BioCryst's. However, BioCryst has shown a remarkable upward trend, with a 186% increase in SG&A expenses from 2014 to 2023, reflecting its aggressive growth strategy. Ionis, while maintaining higher absolute expenses, saw a more modest 15% increase over the same period. This financial trajectory highlights the differing strategic priorities of these two biotech giants, with Ionis focusing on sustained investment and BioCryst on rapid expansion. Such insights are invaluable for investors and industry analysts alike, offering a window into the operational strategies of these companies.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or BioCryst Pharmaceuticals, Inc.
Comparing SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ionis Pharmaceuticals, Inc. Trends and Insights
Ionis Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Annual Revenue Comparison: Ionis Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.
Mesoblast Limited and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared